3Evers S, Ament A, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries[J]. Eur J Clin Microbiol ln-fectDis,2007,26(8):531.
4Higgins JT, Green S. Cochrane handbook for systematic reviews of interventions[EB/OL] (2008-08)[2015-11-12]. http://www.cochrane.org/searctdsite/Cochrance%20review % 27s % 20handbook.
5Constantinos I, Michaelidis BA, Zimmerman RK, et al. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority popu- lations: an exploratory analysis[J]. Value in Health, 2013, 16:(2):311.
6Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western european countries[J]. Clin Infect Dis, 2000, 31 (1) :444.
7Postma MJ, Heijnen MLA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individu- als in the Netherlands[J]. Pharmacoecono, 2001, 19 (2) : 215.
8Carlos CO, Nelson AG, Angel JP, et al. Cost-effective- ness of the introduction of the pneumococcal polysaccha- ride vaccine in elderly Colombian population[J]. Vaccine, 2011,8(29) :7 644.
9Jiang YL, Gauthier A, Annemans L, et al. Cost-effective- ness of vaccinating adults with the 23-valent pneumococ- cal polysaccharide vaccine (PPV23)in Germany[J]. Phar- macoecono & Outcomes Res, 2012,12 ( 5 ) : 645.
10Graeve DD, Lombaert G, Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elder- ly persons in belgium[J]. Pharmacoecono, 2000, 6 (17) : 591.
